Literature DB >> 20685405

Osteopenia and endothelin-1-mediated vasconstrictor tone in postmenopausal women.

Michael L Mestek1, Brian R Weil, Jared J Greiner, Christian M Westby, Christopher A DeSouza, Brian L Stauffer.   

Abstract

Low bone mineral density is highly prevalent in postmenopausal women. Osteopenia in postmenopausal women is a predictor of adverse cardiovascular events. A potential mechanism contributing to the increased cardiovascular risk in postmenopausal women with osteopenia is endothelial vasomotor dysfunction. Endothelin (ET)-1 is a potent vasoconstrictor peptide that is associated with endothelial vasomotor dysfunction and increased cardiovascular risk. Currently, there is no information on osteopenia and ET-1 vasoconstrictor activity in postmenopausal women. We tested the hypothesis that ET-1 mediated vasoconstrictor activity is greater in postmenopausal women with osteopenia compared with those without. Forearm blood flow responses to intra-arterial infusion of BQ-123 (100 nmol/min for 60 min), a selective ET(A) receptor antagonist, were determined in postmenopausal women: 10 with osteopenia (age: 56+/-1 yr, lumbar spine T-score between -1.5 and -2.5) and 12 without osteopenia (age: 60+/-2 yr, T-score>-1.5). In women with osteopenia, forearm blood flow increased approximately 25% (P<0.05) in response to BQ-123. However, in the women without osteopenia, resting forearm blood flow was not significantly changed. In conclusion, these results suggest that osteopenia is associated with greater ET-1-mediated vasoconstrictor tone. Increased ET-1 vasoconstrictor activity may contribute to the elevated cardiovascular risk in postmenopausal women with osteopenia. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20685405      PMCID: PMC2926281          DOI: 10.1016/j.bone.2010.05.041

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  42 in total

1.  Increased activity of endogenous endothelin in patients with type II diabetes mellitus.

Authors:  Carmine Cardillo; Umberto Campia; Melissa B Bryant; Julio A Panza
Journal:  Circulation       Date:  2002-10-01       Impact factor: 29.690

2.  Interactions between nitric oxide and endothelin in the regulation of vascular tone of human resistance vessels in vivo.

Authors:  C Cardillo; C M Kilcoyne; R O Cannon; J A Panza
Journal:  Hypertension       Date:  2000-06       Impact factor: 10.190

3.  Bone mineral density in acute stroke patients: low bone mineral density may predict first stroke in women.

Authors:  L Jørgensen; T Engstad; B K Jacobsen
Journal:  Stroke       Date:  2001-01       Impact factor: 7.914

4.  Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein.

Authors:  Subodh Verma; Shu-Hong Li; Mitesh V Badiwala; Richard D Weisel; Paul W M Fedak; Ren-Ke Li; Bikramjit Dhillon; Donald A G Mickle
Journal:  Circulation       Date:  2002-04-23       Impact factor: 29.690

5.  Oxidative stress modulates osteoblastic differentiation of vascular and bone cells.

Authors:  N Mody; F Parhami; T A Sarafian; L L Demer
Journal:  Free Radic Biol Med       Date:  2001-08-15       Impact factor: 7.376

6.  Endothelin-1 synthesis and endothelin B receptor expression in human coronary artery smooth muscle cells and monocyte-derived macrophages is up-regulated by low density lipoproteins.

Authors:  C Haug; A Schmid-Kotsas; U Zorn; S Schuett; H J Gross; A Gruenert; M G Bachem
Journal:  J Mol Cell Cardiol       Date:  2001-09       Impact factor: 5.000

Review 7.  Endothelin-1 as a mediator in cardiovascular disease.

Authors:  J J Kelly; J A Whitworth
Journal:  Clin Exp Pharmacol Physiol       Date:  1999-02       Impact factor: 2.557

8.  Effects of tumour necrosis factor-alpha in the human forearm: blood flow and endothelin-1 release.

Authors:  J N Patel; A Jager; C Schalkwijk; R Corder; J A Douthwaite; J S Yudkin; S W Coppack; C D A Stehouwer
Journal:  Clin Sci (Lond)       Date:  2002-10       Impact factor: 6.124

9.  Endothelin in the female vasculature: a role in aging?

Authors:  Olga Lekontseva; Subhadeep Chakrabarti; Sandra T Davidge
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2010-01-06       Impact factor: 3.619

10.  Relationship between bone mineral density, bone turnover markers and homocysteine, folate and vitamin B12 levels in postmenopausal women.

Authors:  Berna Haliloglu; Fehime Benli Aksungar; Erdin Ilter; Hakan Peker; Figen Temelli Akin; Nilgun Mutlu; Umit Ozekici
Journal:  Arch Gynecol Obstet       Date:  2009-11-28       Impact factor: 2.344

View more
  4 in total

Review 1.  The Key Role of the Blood Supply to Bone.

Authors:  Massimo Marenzana; Timothy R Arnett
Journal:  Bone Res       Date:  2013-09-25       Impact factor: 13.567

2.  What is the role of bosentan in healing of femur fractures in a rat model?

Authors:  Ali Aydin; Zekai Halici; Erol Akpinar; A Murat Aksakal; Murat Saritemur; Muhammed Yayla; C Semih Kunak; Elif Cadirci; H Tarik Atmaca; S Sena Karcioglu
Journal:  J Bone Miner Metab       Date:  2014-10-09       Impact factor: 2.626

3.  The -839(A/C) Polymorphism in the ECE1 Isoform b Promoter Associates With Osteoporosis and Fractures.

Authors:  Karen E Hansen; Michael G Johnson; Tonia C Carter; John Mayer; Nicholas S Keuler; Robert D Blank
Journal:  J Endocr Soc       Date:  2019-07-15

4.  Bosentan, a drug used in the treatment of pulmonary hypertension, can prevent development of osteoporosis.

Authors:  Duygu Köse; Ahmet Köse; Zekai Halıcı; Elif Çadırcı; Taha Tavacı; Muhammed Ali Gürbüz; Adem Maman
Journal:  Iran J Basic Med Sci       Date:  2021-07       Impact factor: 2.699

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.